Fennec Pharmaceuticals (FENC) Earns Buy Rating from Analysts at Dawson James
Stock analysts at Dawson James assumed coverage on shares of Fennec Pharmaceuticals (NASDAQ:FENC) in a research report issued on Thursday, The Fly reports. The firm set a “buy” rating on the stock.
Other analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Fennec Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Monday, July 16th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Fennec Pharmaceuticals in a research note on Wednesday, June 20th. ValuEngine cut shares of Fennec Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Finally, Wedbush decreased their target price on shares of Fennec Pharmaceuticals from $17.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, September 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Fennec Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $16.75.
NASDAQ FENC opened at $7.79 on Thursday. The firm has a market cap of $155.25 million, a price-to-earnings ratio of -16.64 and a beta of -0.76. Fennec Pharmaceuticals has a fifty-two week low of $7.17 and a fifty-two week high of $14.99.
Several institutional investors have recently modified their holdings of the stock. United Services Automobile Association grew its stake in shares of Fennec Pharmaceuticals by 20.7% in the second quarter. United Services Automobile Association now owns 55,348 shares of the company’s stock worth $578,000 after purchasing an additional 9,500 shares during the last quarter. Granahan Investment Management Inc. MA grew its stake in shares of Fennec Pharmaceuticals by 20.3% in the second quarter. Granahan Investment Management Inc. MA now owns 57,002 shares of the company’s stock worth $595,000 after purchasing an additional 9,626 shares during the last quarter. Creative Planning bought a new stake in shares of Fennec Pharmaceuticals in the second quarter worth $105,000. Cardinal Capital Management grew its stake in shares of Fennec Pharmaceuticals by 116.4% in the second quarter. Cardinal Capital Management now owns 26,047 shares of the company’s stock worth $272,000 after purchasing an additional 14,010 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. bought a new stake in shares of Fennec Pharmaceuticals in the second quarter worth $151,000. 49.78% of the stock is currently owned by institutional investors.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Story: Trading Strategy
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.